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MATRICS consensus cognitive batteryThe validity and signiﬁcance of normal range neurocognition in schizophrenia remain unclear and controversial.We
assessedwhether normal range patients and controls demonstrate evidence of decline relative to premorbid ability
and differ in performance proﬁles across measures, including those external to the normality criterion. In addition,
we compared below normal range healthy control participants with patients at the same ability level. Performance
normality was deﬁned as a MATRICS Consensus Cognitive Battery (MCCB) composite T score between 40 and 60.
Patients (n = 17) and controls (n = 24) meeting the criterion were compared on MCCB domain scores and on
independentmeasuresof readingability, probabilistic andsocial reasoning. Patients (n = 19)andcontrols (n = 20)
scoring below 40 on the MCCB composite were compared on the same set of measures. Cognitively normal range
patients and controls did not differ on estimated premorbid ability or decline and differed only on the Processing
Speed domain of theMCCB. Performance did not differ across other domains or on social and probabilistic reasoning
tasks. Cognitively below normal range patients and controls showedmarked discrepancies between premorbid and
current ability, but there were no group differences. In addition, below normal range groups did not differ on any
MCCBdomain scoreor in termsofexternal cognitivemeasures. Cognitivelynormal rangeschizophreniapatientsmay
be largely indistinguishable from normal range controls, with the exception of processing speed performance. More
typical schizophrenia patients below the normal rangemay be indistinguishable from low-performing controls even
in terms of processing speed.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Cognitive impairment is prevalent in schizophrenia, but substantial
minorities of the patient population perform within normal limits on
many standard measures (Heinrichs, 2005). Mean effect sizes (standard-
ized group differences) for even the most sensitive tasks suggest
considerable distribution overlap between patients and non-psychiatric
control populations. For example, measures of processing speed are
frequently impaired, but aggregated studies imply that approximately
28% of patients and controls overlap in terms of performance (Dickinson
et al., 2007). In a seminal study Palmer et al. (1997) reported that 11% of
their patients demonstrated no impairments across all components of a
comprehensive neuropsychological test battery. Moreover, a small
number of monozygotic twins with schizophrenia score as well or better
than their unaffected co-twins on some cognitive measures (Goldberg
et al., 1995; Torrey et al., 1994). Subsequent reports have supported
the existence of variable proportions of cognitively normal and even
above normal range schizophrenia patients across settings and samples
(e.g. Holthausen et al., 2002; Kremen et al., 2000; Leung et al., 2008;
MacCabe et al., 2012).
Nevertheless, the validity and meaning of cognitive normality
ﬁndings are complicated by dubious classiﬁcation criteria and the
possibility of undetected or under-estimated deﬁcits in patientsc. This is an open access article undmeeting these criteria. For example, an average-range IQ may not
represent normal cognition if performance prior to illness onset was
above average. Proxy measures of premorbid ability like reading skill
reveal declines when compared with current ability in many
schizophrenia patients (Ammari et al., 2014; Weickert et al., 2000).
It follows that differences in estimated premorbid ability may exist
between patients and controls even when there are no differences in
current ability. In addition, summary indices like IQ are problematic in
themselves by combining subtests, thereby obscuring cognitive
strengths and weaknesses (Wilk et al., 2005). This drawback can be
addressed through subtest proﬁle analysis, but recent evidence
suggests that IQ measures fail to capture the true breadth of cognitive
impairment expressed in schizophrenia (Gray et al., 2013). Therefore,
deﬁning cognitive normality primarily in terms of IQ values is
questionable. However, even patients scoring within normal limits
across multiple neuropsychological tasks may have deﬁciencies in
executive, attention-related and motor abilities when compared
directly with healthy control participants (e.g. Allen et al., 2003).
Nonetheless, other studies report no deﬁcits relative to healthy
controls on any measure (Heinrichs et al., 2008) and critics of the
cognitive normality concept acknowledge that “islands” of proﬁcient
function seem to exist. For example, aspects of attention, procedural
memory and emotion processing may be spared in schizophrenia
(Gold et al., 2009).er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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normality with measures that are external to the normality criterion.
It is not surprising to ﬁnd performance similarity between groups on
ability measures used to create the groups in the ﬁrst place. Thus
Muharib et al. (2014) found no differences between schizophrenia
patients and controls on subtests of a cognitive battery when the
composite summary score was used as a normality criterion.
However, independent measures external to the criterion provide a
stronger test of cognitive normality. Thus it is not known whether
cognitively normal range schizophrenia patients differentiate from
healthy controls on specialized tasks with sensitivity to psychotic
psychopathology. Relevant tasks include measures of probabilistic
thinking (Garety and Freeman, 2013) and aspects of social cognition
including Theory of Mind (Mehl et al., 2010) and attribution bias
(Bentall et al., 1994).
A novel and complementary approach to these issues involves the
comparative study of cognitively low-performing, but psychiatrically
unremarkable, control participants. For example, 25% of the general
population scores below the average range on IQmeasures (Wechsler,
2008), thereby approximating the performance level typically found
in schizophrenia. Moreover, more than a third of neurologically
normal adults perform at least a standard deviation below the mean
on multiple neuropsychological test measures even with adjustment
for age and education (Schretlen et al., 2008). Here again, this
performance level is the most frequently reported degree of
impairment observed in schizophrenia patients (Dickinson et al.,
2007; Heinrichs, 2005). However, the low-performing portion of the
general population is seldom accessed to establish control compar-
isons in schizophrenia research. Accordingly, little is known about
whether differences in, say, information processing speed, persist
when patients are compared with low-performing rather than
high-performing healthy controls. This kind of comparison may
reveal cognitive abnormalities intrinsic to schizophrenia and elimi-
nate those that occur as a simple function of general ability level
across populations. In light of these considerations we asked whether
schizophrenia patients meeting or failing to meet a composite
neurocognitive normality criterion differ from healthy control groups
deﬁned by the same criterion in terms of: 1) estimated premorbid
ability; 2) component neurocognitive proﬁles; and 3) independent
measures of probabilistic and social reasoning. In addition, we asked
whether cognitively normal and below normal range patient groups
differ in clinical status and symptom severity.
1. Methods
1.1. Participants
Patients (n = 96) were recruited from several programs in
Hamilton, Ontario, Canada: the Cleghorn Early Intervention Clinic
(St. Joseph’s Healthcare Hamilton), the Hamilton Program for
Schizophrenia, the Schizophrenia Outpatient Clinic (St. Joseph’s
Healthcare Hamilton), Schizophrenia Services of Ontario, Hamilton
Chapter, Path Employment Services and the Wellington Psychiatric
Outreach Program. Criteria for study entry included: 1) a diagnosis of
schizophrenia or schizoaffective disorder conﬁrmed by the Structured
Clinical Interview for DSM-IV Axis I Disorders (First et al., 1996), with
no concurrent diagnosis of substance use disorder; 2) a history free of
developmental or learning disability; 3) history free of neurological or
endocrine disorder; and 4) age 18–65. Healthy control participants
(n = 144) were recruited through local newspaper and online
classiﬁed advertisements for paid research participation. Interested
individuals were screened for psychiatric history and substance use
disorders. All participants provided written informed consent and the
research was approved by institutional ethics review boards.1.2. Measures
Standard cognitive tests forming the criterion for performance
normality comprised the MATRICS (Measurement and Treatment
Research to Improve Cognition in Schizophrenia) Consensus Cognitive
Battery (MCCB; Nuechterlein et al., 2008). The MCCB includes
individual measures of working memory, attention, verbal memory,
processing speed, reasoning and problem-solving, visual learning and
social cognition and yields a composite index of overall performance.
The following adjunct cognitive tests were included. Early or
premature decision-making in probabilistic reasoning (“jumping to
conclusions”) was measured with the classic “beads” task described
by Garety and Freeman (2013). The task requires participants to
decide from which of 2 “jars” individually-presented colored “beads”
were drawn. One jar contained a ratio of red to blue beads of 60:40
and a second jar contained the same ratio of blue to red beads. The
number of trials or “draws” prior to decision was recorded as the
dependent variable.
Two aspects of social cognition with demonstrated sensitivity to
positive symptoms were also measured. Externalizing attributions for
negative events were measured with the Internal, Personal and
Situational Attributions Questionnaire (IPSAQ) developed and vali-
dated by Kinderman and Bentall (1996). The IPSAQ provides brief
situational descriptions and elicits attributions by posing questions
and providing responses in a multiple choice format. An Externalizing
Bias score is calculated by subtracting the number of negative internal
attributions from the number of internal positive attributions.
Theory-of-Mind, or reasoning about the mental states of other people,
was measured with the Reading the Mind in the Eyes test
(Baron-Cohen et al., 2001). This is a visual task that involves inferring
thoughts and emotions from photographs of a person’s eyes. The
Reading subtest of the Wide Range Achievement Test (WRAT-4) was
used to estimate premorbid cognitive ability (Johnstone andWilhelm,
1996). In addition, a premorbid–current ability discrepancy score was
created by transforming the Reading standard score into a T score and
subtracting the MCCB composite T score from this value. Similar
discrepancy scores have been used to index premorbid–current ability
differentials by Ammari et al. (2014), Badcock et al. (2005), Harvey et
al. (2006) and O’Connor et al. (2012). Clinical state and symptom
severity were measured with the Positive and Negative Syndrome
Scale (PANSS; Opler et al., 1999).
1.3. Group assignment procedure and data analysis
Group assignment was based on MCCB composite scores summa-
rizing performance across 7 ability domains, with a T score of 50 ± 10
representing normative mean performance in the community
standardization sample and in line with previous studies using this
instrument (Kern et al., 2004, 2011; Muharib et al., 2014). Accord-
ingly, the criterion for assignment to cognitively normal-range groups
was an overall composite T score from 40 to 60. Application of this
performance criterion to the pool of 96 patients yielded 17 with
normal-range ability. Given the low prevalence (18%) of normal range
MCCB performance and to ensure demographic similarity with
comparison subgroups, these patients’ age range and gender
proportion along with composite scores were used as criteria in
assigning controls to a normal range ability group. Hence, inclusion
criteria for the normal range control group were: 1) age 25–50; 2)
gender ratio 50%–60% male; and 3) MCCB composite T score between
40 and 60. A total of 24 controls in the pool of 144 community-based
non-psychiatric participants met these criteria. Cognitively below-
normal range was deﬁned as a composite T score from 20 to 39.
Applying this criterion to the pool of community participants yielded
n = 20 below normal range control participants. Demographic and
Table 1
Descriptive and criterion data for cognitively normal range (CNR) and below normal range (BNR) patients and controls.
Variable CNR Patients (n = 17) CNR Controls (n = 24) BNR Patients (n = 19) BNR Controls (n =20) Statistic
Age, yrs (M, SD) 34.47 (7.71) 35.54 (9.34) 38.37 (8.19) 38.70 (8.19) F3, 76 = 1.12
High school completion (%) 100 92 68 80 χ 32 = 8.32⁎
Skilled parental occupation (%) 81 74 56 64 χ 32 = 2.76
Gender (males %) 59 54 63 50 χ 32 = 0.77
First language English (%) 82 100 89 80 χ 32 = 5.28
MCCB composite T (M, SD) 46.94 (5.00) 48.54 (6.11) 25.58 (5.43) 24.50 (9.33) F3, 76 = 77.08⁎⁎
Note: MCCB = MATRICS Consensus Cognitive Battery.
⁎ p b .05.
⁎⁎ p b .001.
229R.W. Heinrichs et al. / Schizophrenia Research: Cognition 2 (2015) 227–232psychometric data from this group were used to set inclusion criteria
for the below normal range patients as follows: 1) age 20–53; 2) ratio
50%–60% males; and 3) MCCB composite T score between 20 and 39.
These requirements weremet by n = 19 patients whowere therefore
assigned to the below normal-range category.
The primary contrasts of interest in theMCCB proﬁle analysis were
between cognitively normal patients and controls and between
below-normal range patients and controls rather than between
normal and below-normal range groups. Therefore, and to economize
on statistical testing, group differences (normal range patients versus
normal range controls and below normal range patients versus below
normal range controls) were assessed with t tests adjusted for
multiple comparisons rather than with analysis-of-variances
methods. However, analysis of adjunct cognitive measures included
all four groups within a multivariate analysis-of-variance (MANOVA)
approach (SPSS Version 22). This was done following Box’s tests for
covariance matrix inequality and Levene tests for variance inequality.
2. Results
Table 1 shows corresponding descriptive statistics for all 4 study
groups. Patient and control subgroups did not differ signiﬁcantly on any
variable except educational achievement. High school completion rates
were lower in cognitively below normal-range patients relative to
normal-range patients (χ 12 = 6.44; p b .05) and controls (χ 12 = 3.78;Fig. 1. Performance proﬁles on theMATRICS Consensus Cognitive Battery (MCCB) in schizophreni
(normal range) and b 40 (below normal range). The Processing Speed difference between cognitp = .05).However, rateswereequivalent inbelownormal-rangepatients
and controls and in normal range patients and controls.
MCCB performance proﬁles for patient and healthy comparison
groups are presented in Fig. 1. First, cognitively normal-range patients
and controls were compared on each domain index T score. This
revealed a signiﬁcant group difference on the Processing Speed
comparison (t (39) = −2.83, p b .05) indicating lower patient scores
relative to controls. In addition, 11/17 or 65% of the patients obtained
T scores b 40 on this index despite meeting the normal range
composite score criterion (T ≥ 40). The remaining differences be-
tween normal range patients and controls were non-signiﬁcant across
the Reasoning and Problem-Solving, Attention, Working Memory,
Verbal Learning, Visual Learning and Social Cognition indices. The
next comparison comprised below normal range patients and controls
and yielded no signiﬁcant group differences for any MCCB index.
Results for adjunct cognition measures are presented in Table 2.
Levene tests for error variance inequality were non-signiﬁcant for
each variable except Reading/MCCB Discrepancy. Therefore, data for
this variable were transformed to positive values and further
subjected to square root transformation. This yielded a non-
signiﬁcant Levene test. Box’s test of covariance matrix inequality
was also non-signiﬁcant. Accordingly, a multivariate analysis-of-
variance (MANOVA) was carried out with group as the independent
factor and WRAT Reading, Reading/MCCB Discrepancy, Reading the
Mind in the Eyes total correct, “bead” task draws-to-decision anda patients and healthy control participantswithMCCB composite T scores between 40 and 60
ively normal range patients and controls was signiﬁcant after Bonferonni correction.
Table 2
Cognitively normal (CNR) and below normal range (BNR) patient and control group comparisons on MCCB and WRAT-4 measures.
1.CNR Patients (n = 17) 2.CNR Controls (n = 24) 3.BNR Patients (n = 19) 4.BNR Controls (n = 20) F (3, 75) Post hoc Comparisons⁎
WRAT-4 Reading 100.53 (6.17) 101.08 (8.76) 85.68 (8.04) 85.00 (7.79) 24.24⁎ 1 N 3,4; 2 N 3,4
Reading/MCCB discrepancy 3.44 (6.91) 2.17 (5.06) 14.79 (6.42) 15.42 (9.32) 18.72⁎ 1 b 3,4; 2 b 3,4
Trials-to-decision (Beads task) 10.29 (2.42) 8.67 (4.56) 6.06 (4.83) 5.05 (3.30) 6.86⁎ 1 N 3,4; 2 N 4
Reading the Mind in the Eyes 25.71 (3.16) 26.17 (3.62) 10.68 (2.54) 10.95 (3.33) 12.78⁎ 1 N 3,4; 2 N 3,4
Externalizing Bias 3.06 (4.19) 2.62 (3.84) 0.50 (3.13) 2.95 (3.72) 1.88
Note. MCCB = MATRICS Consensus Cognitive Battery composite T score; WRAT-4 = Wide Range Achievement Test-4 (standard score).
⁎ p b .05.
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indicated a signiﬁcant main effect of group (F 15, 196 = 10.03,
p b 0.001, partial Ƞ2 = .407). Univariate F ratios showed signiﬁcant
group differences for all dependent variables except Externalizing
Bias. Additional testing of group means corrected for multiple
comparisons revealed that cognitively normal patients and controls
did not differ on any measure. Similarly, there were no differences
between cognitively below normal range patients and controls.
However, there were signiﬁcant differences on several indices
between patient and control normal range relative to both below
normal range groups. This included WRAT-4 Reading/MCCB compos-
ite discrepancies, which were signiﬁcantly larger in both below
normal range groups. Finally, analysis of the clinical and functional
status data (Table 3) for the patient groups showed no signiﬁcant
differences in mean Positive, Negative or General Psychopathology
PANSS scores or in terms of illness length and frequency of second
generation antipsychotic medication use or in living situation and
employment.
3. Discussion
The data presented above suggest that the study of normal range
cognition is a valuable complement to the analysis of cognitive
impairment in schizophrenia. We found no evidence that estimated
premorbid ability distinguishes normal range patients from control
participants. In addition, this similarity of estimated premorbid ability
also applied to more typical cognitively impaired patients relative to
controls falling below the normality criterion. However, both below
normal range patients and controls had substantial discrepancies
between premorbid and current abilities and differed in this respect
from normal range groups. Proﬁle comparisons of component test
battery scores revealed no signiﬁcant differences between cognitively
normal-range patients and controls on 6 of 7 indices. The exception
was the Processing Speed index, comprising timed paper-and-pencil
measures of symbol coding, response generation and sequencing. InTable 3
Patient characteristics.
Cognitively Normal
Range (n = 17)
Below-Normal
Range (n = 19)
Duration of illness (yrs), mean (SD) 10.59 (8.68) 14.96 (10.48)a
2nd generation antipsychotic drugs 13 11
Diagnosis
schizophrenia, n (%) 10 (59) 12 (63)
schizoaffective, n (%) 7 (41) 7 (37)
PANSS Positive T score, mean (SD) 38.82 (6.19) 42.94 (8.12)
PANSS Negative T score, mean (SD) 37.29 (7.73) 38.50 (6.84)
PANSS General T score, mean (SD) 37.65 (6.68) 41.94 (8.03)
Independent living situation, n (%) 9 (53) 8 (42)
Paid employment, n (%) 3 (18) 4 (23)a
Note. PANSS = Positive and Negative Syndrome Scale.
a n = 17.contrast, processing speed differences were not found in patients and
controls with below normal-range cognition. In terms of social and
probabilistic reasoning, we found no differences between patients and
control participants at normal range or below normal range ability
levels although, again, there were marked differences between ability
levels. Finally, despite differing in cognitive performance, patient
subgroups did not differ signiﬁcantly in symptom severity or in other
aspects of clinical and functional status.
These results are consistent with earlier reports of slowed
processing speed in cognitively normal range patients relative to
controls (Holthausen et al., 2002; Vaskinn et al., 2014). However, no
other cognitive differencewas detected in the normal range groups. In
addition, to our knowledge, this is the ﬁrst comparison of below
normal range control participants and schizophrenia patients and the
processing speed difference did not occur for these groups. It is
possible that the large group differences reported in the literature
reﬂect comparisons between cognitively impaired patients and
cognitively normal rather than below normal range control partici-
pants. Nevertheless, this does not account for the special sensitivity of
processing speed tasks at higher joint ability levels. Recent evidence
suggests that these tasks associate speciﬁcally with white matter
integrity (Karbasforoushan et al., 2015). Therefore, a further possi-
bility is that the general cognitive deﬁcit observed across multiple
domains in most schizophrenia patients is absent or virtually absent
in a minority, but with reduced connectivity and hence slowed
processing persisting as a residual weakness.
Comparing normal and below-normal ability range patients with
corresponding control groups invariably entails sampling from
different portions of the respective population distributions and the
application of arbitrary, albeit conventional, deﬁnitions of “normal-
ity.” Different deﬁnitions may yield somewhat different results
(Heinrichs et al., 2013). Moreover, group comparisons of normal
range patients and controls require drawing from the upper end of the
patient performance distribution, but from the central tendency of
controls. Conversely, comparing below-normal range patients and
controls means drawing from the patient central tendency and the
lower end of the general population distribution. When these
distributions comprise scores from an aggregate performance index
like theMCCB, any subsequent statistical comparison using sub-scores
is likely to recapitulate the typology. This situation underscores the
importance of group comparisons with measures not included in the
normality criterion.
Several aspects of cognition not measured by the MCCB, including
probabilistic reasoning (“jumping to conclusions”) and Theory of
Mind processes, have been hypothesized as mediators of psychotic
psychopathology, especially delusions (Garety and Freeman, 2013).
Our data suggest that performance on even these specialized tasks
fails to distinguish schizophrenia patients from controls at both the
below-normal and normal range ability levels. This result thereby
supports the validity of our typology. In addition, lack of symptomatic
differentiation, especially positive symptom severity, in cognitively
normal and impaired patients is reported frequently in the literature
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across cognitive ability is consistent with the weak or absent relations
between symptom dimensions and standard cognitive performance
measures observed in schizophrenia (Dominguez et al., 2009). These
ﬁndings imply a psychotic disease process that exists in parallel with
cognitive pathology and without substantial attenuation when
cognition is relatively proﬁcient. Nonetheless, the high prevalence of
cognitive impairment in the disorder suggests that comorbidity of
psychotic and cognitive pathologies is the most typical form of illness.
Similar kinds of comorbidity, whereby two disorders co-occur at high
rates, but vary independently in terms of their severity, appear to exist
in neurology and psychiatry (Frías et al., 2014; Shindo et al., 2013).
Our study was limited by the small sample size of cognitively
normal-range schizophrenia patients, a subpopulation thatmay comprise
only 15%–20% of outpatients with the disorder. In addition, with upper
ages in the 50s it is unclear whether our ﬁndings apply to older patients.
However, it is notable that Leung et al. (2008) found a normality rate of
18.5% in their study of middle-aged and elderly outpatients, which
compares favorably with our rate of 17%. Nevertheless, a possible
consequence of small samples is inadequate power in detecting group
differences in performance proﬁles, especially following correction
procedures for multiple comparisons. Determining the validity of
cognitive normality in schizophrenia highlights the challenge of adequate
recruitment from a small portion of the schizophrenia patient population.
It is noteworthy that relatively rare subgroups continue to receive study
and provide valuable data to schizophrenia research. They include
velocardiofacial syndrome (Prasad et al., 2008) and pediatric onset
(Clemmensen et al., 2012) patients.
In conclusion, cognitive deﬁcits occur very frequently in schizo-
phrenia, but this occurrence does not prove that psychosis and
deﬁcient cognition are causally linked or mutually reducible. The data
presented here show that small, but substantial numbers of patients
exist with largely normal cognitive proﬁles, even in terms of tasks
selected for their sensitivity to psychotic psychopathology. Informa-
tion processing speedmay be unique in its persisting weakness in this
patient subpopulation. At the same time, more typical and hence
impaired patients are cognitively indistinguishable from low per-
forming healthy people on these same tasks. Moreover, the symp-
tomatic severity of the clinical illness does not appear to differ in
cognitively high and low-performing patients. Therefore our ﬁndings
support and extend previous reports of cognitive normality in the
literature and argue for the careful biobehavioral study of these
exceptional individuals.
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